Halozyme Therapeutics, Inc. $HALO Stake Lessened by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,056 shares of the biopharmaceutical company’s stock after selling 9,168 shares during the period. Segall Bryant & Hamill LLC owned 0.25% of Halozyme Therapeutics worth $19,263,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Element Squared LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $1,193,000. Mizuho Markets Americas LLC grew its position in Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after buying an additional 926,526 shares during the last quarter. Paragon Capital Management Inc. bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $1,273,000. Hussman Strategic Advisors Inc. increased its holdings in shares of Halozyme Therapeutics by 66.7% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock valued at $3,533,000 after buying an additional 21,000 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Halozyme Therapeutics by 19,326.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock valued at $5,753,000 after acquiring an additional 85,036 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $82.54 on Friday. The stock has a market cap of $9.79 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The business has a fifty day simple moving average of $74.52 and a 200-day simple moving average of $70.93. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12 month low of $58.53 and a 12 month high of $84.44.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the company posted $1.11 earnings per share. Halozyme Therapeutics’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,477 shares of company stock worth $5,102,643 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HALO shares. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.